COVID-19：Medicago VLP疫苗第1阶段测试结果：MT-2766
-关于VLP疫苗的1期临床试验结果的公告-
田边三菱制药：
Medicago：加拿大魁北克，合并子公司
Medicago目前正在开发旨在预防COVID-19的VLP疫苗。
进行了植物来源的病毒样颗粒（VLP *）疫苗（开发号：MT-2766）的1期临床试验。
我们很高兴地通知您，我们已经宣布我们取得了良好的成绩。 </ s> </ s> </ s>
该1期临床试验的概述和结果如下。
田边三菱制药
https://www.mt-pharma.co.jp/news/2020/MTPC201111.html
Initiatives Against COVID-19 in Canada
– Phase 1 Results for COVID-19 Vaccine Candidate
November 11, 2020
Mitsubishi Tanabe Pharma Corporation
announced today that
its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; CEO; Bruce D. Clark)
has announced the positive results of the Phase 1 clinical trial of its plant-derived virus-like particle (VLP) vaccine (project code:MT-2766) for the prevention of coronavirus disease 2019 (COVID-19) which has being developed by Medicago.
The summary of the Phase 1 clinical study and results are as follows:
■Subjects: 180 healthy Canadian subjects, male and female aged 18-55.
■Dosage and administration: Evaluated dosages of 3.75, 7.5 or 15 μg of the VLP vaccine candidate alone or with each of the two adjuvants – GSK’s adjuvant and Dynavax’s adjuvant after two doses.
■Endpoints: Safety and immunogenicity.
■Results: Induced robust neutralizing antibody and cellular immune response in the adjuvant group.
No severe adverse events were observed.
Based on the overall data profile,
Medicago plans to proceed with the Phase 2/3 clinical trial, subject to regulatory approval.
Mitsubishi Tanabe Pharma Group will work to develop and deliver MT-2766 to society as soon as possible, contributing even further to the prevention of COVID- 19, a pressing social issue.
Medicago release (November 10, 2020, local time) Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate.
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC201111.pdf
Medicago announces positive Phase 1 results for its COVID-19 vaccine candidate
QUEBEC CITY, November 10th, 2020 – Medicago, a biopharmaceutical company headquartered in Quebec City,
is pleased to report interim results of the Phase 1 clinical trial of its plant-derived vaccine for COVID-19.
The results of the trial demonstrated that 100 per cent of subjects developed a promising antibody response after two doses of Medicago’s COVID-19 adjuvanted vaccine candidate.